Small Cap Feast

17th August 2022

Dish of the day
No Joiners today
Off the menu
No leavers today
Dish Of The Day:
No joiners today
Off The Menu:
Altus Strategies Plc has left AIM.

What’s Cooking In The IPO Kitchen?

Unigel Group, intends to join the Aquis Growth Market. Unigel Group is a pioneer in the field of thixotropic gels for the fibre optic cable industry. The Company is also a supplier of laminated steel tapes to the fibre optic cable industry in the US. Thixotropic gels and laminated steel tapes are essential components to the rapidly growing global fibre optic cable market. The Group exports to over 40 countries and is a key supplier to almost every leading fibre optic cable manufacturer worldwide and is the industry’s only organisation with multiple manufacturing facilities spread across 3 continents. The Company acts as the holding company for its wholly-owned operating subsidiary, Unitape Limited and its 60% owned operating subsidiary, Unigel (UK) Limited. Delayed, timing TBC.

Georgina Energy, an early-stage resource company with a strategy of actively pursuing the exploration, commercial development and monetisation of helium, hydrogen and hydrocarbon interests located in the Amadeus and Officer Basins in Northern and Western Australia intends to join AIM. Georgina Energy has two principal onshore interests. The first, the Mount Winter Prospect is located in the Amadeus Basin in Northern Australia, which the Company has a right to earn an initial 75% interest. The second interest, the Hussar Prospect is 100% owned by the Company and is located in the Officer Basin in Western Australia. Expected late September.

Breakfast Buffet

Cambridge Cognition 133.5p £41.6m (COG.L)

The developer of digital solutions to assess brain health, announces that it will be collaborating with the University of Oxford by providing cognitive assessments for the Impact of Semaglutide in Amyloid Positivity (ISAP) study. As a consequence Cambridge Cognition expects to receive validation data for its voice-based solution, NeuroVocalixTM. The randomised controlled trial, sponsored by the University of Oxford and funded by Novo Nordisk, aims to investigate the effectiveness of a diabetes medication (oral semaglutide) against the neuropathophysiology of Alzheimer’s disease (specifically, tau accumulation and neuroinflammation).

Colefax Group 807.5p £64.1m (CFX.L)

The designer and distributor of furnishing fabrics & wallpapers and the owner of an interior decorating business, announces its preliminary results for the year ended 30 April 2022. Sales increased by 31% to £101.80m (2021: £77.91m). Pre-tax profit increased by 100% to £10.82m (2021: £5.42m), reflecting operational gearing in the Fabric Division and an exceptional performance by the Decorating Division. Management indicates that the company’s position at the premium end of the market should provide some protection from inflation. In addition, Colefax is benefitting from the recent strengthening of the US Dollar as over 60% of its Fabric Division revenues are in the US.

Future Metals 6.4p £22.7m (FME.L)

The Australian based exploration company announce that it has received firm commitments to subscribe for 40m fully paid ordinary shares (Placement Shares) at $0.125 per share to raise $5.0m (Placement). The Placement includes the issue of one free listed attaching option (Placement Options) for every three Placement Shares and Placement Options are issued on the same terms as the existing listed option class; FMEO, exercisable at a price of $0.10 per share and an expiry date of 11 June 2024. In conjunction with the Placement, Future Metals will be offering eligible shareholders the opportunity to participate in a Share Purchase Plan (SPP) on the same terms as the Placement to raise up to an additional $0.5m. Net proceeds will be utilised on exploration activities to test Panton’s Ni-Cu-PGE sulphide potential.

Gattaca 75.0p £24.2m (GATC.L)

The specialist Engineering and Technology staffing solutions business, provides a trading update for the year ended 31 July 2022 (FY22). Net fee incomes are expected to be £44.0m, up 4% from £42.1m in FY21. The company expects its continuing underlying PBT for the full year to be in line with market consensus of break even. The company remains confident in the long-term fundamentals of the STEM markets, given the shortage of candidates.

Gooch & Housego 659.0p £165.0m (GHH.L)

The manufacturer of photonic components & systems, provides a trading update. As at 31 July 2022, the order book stood at a record £140.6m (31 July 2021: £97.7m), up 43.9% year-on-year. However, capacity expansion in the second half of the financial year has been constrained by the competitive labour markets in the UK and the US, as well as supply chain shortages. Hence, adjusted profit before tax is now forecast to be around £3.5m lower than management’s previous expectations and management will review intangible asset carrying values and make any required adjustments for year end. For FY23, the company expects double-digit volume growth and positive EBIT margin.

Libertine Holdings 19.0p £26.5m (LIB.L)

The developer of clean, highly efficient and fuel-flexible Linear Generator products, announces its audited results for the year ended 31 March 2022 (FY 2021/22). Total revenue (including grant incomes) was £2.9m (FY 2020/21: £0.1m). Net loss widened to £3.2m due to exceptional items and net interest charges (FY2020/21: £0.7m in net loss). The cash balance was £6.7m (FY2020/21 unaudited: £0.3m) with £9.0m raised, before £1.5m of share issue and IPO costs. The company has completed its LGN120 prototype and will focus on brining its Linear Generator technology to market.

Nightcap 14.75p £29.2m (NGHT.L)

The owner of the Cocktail Club, the Adventure Bar Group and the Barrio Familia group of bars, announces that it has agreed a £10.0m debt refinancing facility with HSBC. The new debt facility is to consolidate existing debt facilities, totalling £5.5m. The remaining £4.5m under the new HSBC debt facility is reserved for capital expenditure on new sites both in London and in key cities across the UK. The company’s cash position (including cash in transit) as at 3 July 2022 was £6.1m.

Oxford Metrics £101.5p £131.7m (OMG.L)

The smart sensing software company announces a contract win with Dark Matters in France for its Vicon solution in motion measurement. Based in the Greater Paris, Dark Matters is a full-service studio for high-end filmmaking specialising in virtual and real-time production. Its virtual production stage will house 60 Vicon Vero cameras plus Shōgun software, enabling performance capture and live camera tracking for in-camera visual effects (ICVFX).

Sanderson Design Group 106.0p £75.2m (SDG.L)

The luxury interior design and furnishings group, announces its collaboration with Disney. Under the terms of the licensing agreement, the Sanderson brand will be able to create wallpapers and fabrics based on a wide range of Disney Classic franchises, including Mickey Mouse and Minnie Mouse and Snow White and the Seven Dwarfs, dating back to the 1930’s. Products developed under the new agreement will be distributed internationally, including North America, EMEA, APAC and South-East Asia.

Serabi Gold 43.0p £32.6m (SRB.L)

The Brazilian-focused gold mining and development company, provides an update from its operations in the Tapajos region of Para State, Northern Brazil. Total production in July was 2,703 ounces, including contribution of 241 ounces from the Coringa project. Serabi remains on course to meet its production guidance of 30,000 ounces for 2022. Given the stabilised production levels, the company intends to revert to reporting gold production on a quarterly basis going forward.

17 August 2022
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged


Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram